SCHEMBL191689

SCHEMBL191689

Cc1csc(Nc2cc(Oc3c(F)cccc3F)ccn2)n1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GCK P35557 10/20 0.52
TRPV4 Q9HBA0 1/20 0.45
KCNN1 Q92952 1/20 0.45
KCNN2 Q9H2S1 1/20 0.45
KCNN3 Q9UGI6 1/20 0.45
RAB9A P51151 4/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
NPC1 O15118 3/20 0.44
CASP3 P42574 3/20 0.44
SENP8 Q96LD8 3/20 0.44
SENP7 Q9BQF6 3/20 0.44
SENP6 Q9GZR1 3/20 0.44
SLC2A1 P11166 1/20 0.44
GRM5 P41594 2/20 0.43
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190744 0.88 TRPV4 (0.47) GCKTRPV4KCNN1KCNN2KCNN3
SCHEMBL191171 0.86 GRM5 (0.45) GCKTRPV4KCNN1KCNN2KCNN3
SCHEMBL190863 0.85 GCK (0.49) GCKTRPV4KCNN1KCNN2KCNN3
SCHEMBL191295 0.85 GCK (0.49) GCKTRPV4KCNN1KCNN2KCNN3
SCHEMBL192191 0.84 GCK (0.47) GCKTRPV4KCNN1KCNN2KCNN3
SCHEMBL190426 0.83 KCNN1 (0.61) KCNN1KCNN2KCNN3RAB9AKMT2A
SCHEMBL190602 0.83 NPC1 (0.58) GCKKCNN1KCNN2KCNN3RAB9A
SCHEMBL190433 0.83 RAB9A (0.55) GCKTRPV4KCNN1KCNN2KCNN3
SCHEMBL191023 0.83 GRM5 (0.43) GCKTRPV4KCNN1KCNN2KCNN3
SCHEMBL190659 0.83 GCK (0.59) GCKTRPV4KCNN1KCNN2KCNN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 GCK 2/4885TRPV4 4775/4885KCNN1 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.